CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
<< View More Conferences
2nd Annual Live Medical Crossfire® : Hematologic Malignancies
Oncology Conference Multimedia
View more videos >>
Dr. Hobbs on the Updated NCCN Guidelines in CML
Dr. Brander on the Treatment Landscape for Patients With High-Risk CLL
Dr. Pinilla-Ibarz Discusses Advancements in CML
Oncology Conference Articles
Expert Shares Insights on CLL Treatment Paradigm
Jacqueline D. Barrientos, MD, MS, discusses the current treatment landscape for CLL, highlights some of the biggest challenges for physicians, and gives her insight on how to move forward in the field.
Immunotherapy at the Forefront of ALL Treatment, Expert Says
Major advancements in immunotherapy are at the forefront of treatment for patients with acute lymphoblastic leukemia.
Immunotherapy Treatment Options Continue to Grow in Relapsed/Refractory Multiple Myeloma
Sham Mailankody, MBBS, discusses current treatment options and shifting preferences, especially toward triplet combinations, as well as emerging immunotherapy treatment options in multiple myeloma.
Despite New Treatments in CLL, Comparative Data and Guidance Slow to Emerge
With newer agents approved for patients with chronic lymphocytic leukemia, physicians are now challenged with how best to utilize them.
Pembrolizumab Data Reviewed in Classical Hodgkin Lymphoma
George F. Geils, Jr, MD, discussed the clinical efficacy and adverse event management techniques for pembrolizumab as a treatment for patients with classical Hodgkin lymphoma.
CAR T-cell Therapies Offer Hope for DLBCL
Chimeric antigen receptor T-cell therapies have quickly moved from early phase clinical trials to FDA approval for diffuse large B-cell lymphoma, with research now exploring ways to shift these agents earlier in the treatment paradigm.
Expert Discusses the Discontinuation of TKIs in Treatment Landscape of CML
Gabriela S. Hobbs, MD, discusses how discontinuing tyrosine kinase inhibitors will change the treatment landscape and other strategies for treating patients with chronic myeloid leukemia.
FDA Approvals in Myeloma and aTTP, Priority Review Designations in RCC and HNSCC, and More
PARP Inhibitors Hold Promise in mCRPC and Biallelic DNA Repair Gene Defects
Novel Agents Spark New Approaches for Triple-Negative Breast Cancer
Pembrolizumab/Cabozantinib Combo Is Well Tolerated, Shows Activity in Metastatic RCC
Pembrolizumab Shows Promising Activity in Non-Clear Cell RCC
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.